Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Monoclonal antibody technology.

J A Tami, M D Parr, S A Brown

American Journal of Hospital Pharmacy

|November 1, 1986

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1.

Clinical and experimental immunology·2005

Same author

A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.

Gut·2004

Same author

Pulmonary vasodilation in the rat by insulin in vitro could indicate potential hazard for inhaled insulin.

Diabetologia·2003

Same author

Altered response to adaptive signals in transplanted intestine.

Transplantation proceedings·2002

Same author

Measurement of the electron affinity of cerium.

Physical review letters·2002

Same author

Nutritional effects of surgical and medical treatment for short bowel syndrome.

JPEN. Journal of parenteral and enteral nutrition·2001

Same journal

National health care reform, Part 2: Response to pharmacists.

American journal of hospital pharmacy·1994

Same journal

Validity of originality assessment.

American journal of hospital pharmacy·1994

Same journal

Unit dose dispensing of chromic phosphate P 32 suspension.

American journal of hospital pharmacy·1994

Same journal

Hydralazine injection still available.

American journal of hospital pharmacy·1994

Same journal

Improved extemporaneous formulation of cyclosporine ophthalmic drops.

American journal of hospital pharmacy·1994

Same journal

Paclitaxel diluent and the case of the slippery spike.

American journal of hospital pharmacy·1994

See all related articles

Monoclonal antibody (MoAb) technology, developed in 1975, produces specific antibodies for diagnostics and potential therapies. Current production methods have limitations, but MoAb applications in healthcare are expanding.

Area of Science:

Biotechnology
Immunology
Cell Biology

Background:

Monoclonal antibodies (MoAbs) are highly specific proteins derived from a single clone of cells.
The hybridoma technology, developed in 1975, is a cornerstone for MoAb production.
MoAbs bind to a single epitope on a specific antigen.

Purpose of the Study:

To present the development, production, limitations, and diverse uses of monoclonal antibody technology.
To highlight the significance of MoAbs in various scientific and medical fields.
To inform about the expanding applications and the need for understanding MoAb functions.

Main Methods:

Hybridoma technology: fusion of antibody-producing spleen cells with myeloma cells.
Large-scale production of MoAbs via cell cultures or in vivo (mouse peritoneum).

Related Experiment Videos

Harvesting and purification of MoAbs for various applications.

Main Results:

MoAbs are produced in large quantities using established hybridoma techniques.
Production limitations include potential viral contamination and insufficient yield.
MoAbs are effective in diagnostic tests (pregnancy, drug assays, infection, cancer detection) and imaging.

Conclusions:

Monoclonal antibody technology has evolved significantly since its inception.
Despite production challenges, MoAbs offer broad utility in diagnostics and therapeutics.
Increased use of MoAbs in healthcare necessitates a strong understanding among professionals, including pharmacists.